Soumya Gangopadhyay

Soumya Gangopadhyay is a Associate Principal Scientist, Bioanalysis at Verve Therapeutics with expertise in molecular and cell-based assays. Prior to joining Verve, Dr. Gangopadhyay worked at Intellia Therapeutics, developing several molecular assays for CRISPR-Cas9 based pre-clinical in-vivo and ex-vivo gene editing programs. Dr. Gangopadhyay received her Ph.D. from Syracuse University where she identified the amino acid residues involved in substrate specificity of GGTase-I, an enzyme that post-translationally modifies several Rho GTPases. She then completed a postdoctoral fellowship at the Broad Institute where she worked on developing technologies to modulate Cas9 activity using small molecules and light.